The Library
EAU Guidelines on primary urethral carcinoma
Tools
Gakis, Georgios, Witjes, J. Alfred, Compérat, Eva, Cowan, Nigel C., De Santis, Maria , Lebret, Thierry, Ribal, Maria J. and Sherif, Amir M. (2013) EAU Guidelines on primary urethral carcinoma. European Urology, Volume 64 (Number 5). pp. 823-830. doi:10.1016/j.eururo.2013.03.044 ISSN 0302-2838.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1016/j.eururo.2013.03.044
Abstract
Context
The European Association of Urology (EAU) Guidelines Group on Muscle-Invasive and Metastatic Bladder Cancer prepared these guidelines to deliver current evidence-based information on the diagnosis and treatment of patients with primary urethral carcinoma (UC).
Objective
To review the current literature on the diagnosis and treatment of patients with primary UC and assess its level of scientific evidence.
Evidence acquisition
A systematic literature search was performed to identify studies reporting urethral malignancies. Medline was searched using the controlled vocabulary of the Medical Subject Headings database, along with a free-text protocol.
Evidence synthesis
Primary UC is considered a rare cancer, accounting for <1% of all malignancies. Risk factors for survival include age, tumour stage and grade, nodal stage, presence of distant metastasis, histologic type, tumour size, tumour location, and modality of treatment. Pelvic magnetic resonance imaging is the preferred method to assess the local extent of urethral tumour; computed tomography of the thorax and abdomen should be used to assess distant metastasis. In localised anterior UC, urethra-sparing surgery is an alternative to primary urethrectomy in both sexes, provided negative surgical margins can be achieved. Patients with locally advanced UC should be discussed by a multidisciplinary team of urologists, radiation oncologists, and oncologists. Patients with noninvasive UC or carcinoma in situ of the prostatic urethra and prostatic ducts can be treated with a urethra-sparing approach with transurethral resection and bacillus Calmette-Guérin (BCG). Cystoprostatectomy with extended pelvic lymphadenectomy should be reserved for patients not responding to BCG or as a primary treatment option in patients with extensive ductal or stromal involvement.
Conclusions
The 2013 guidelines document on primary UC is the first publication on this topic by the EAU. It aims to increase awareness in the urologic community and provide scientific transparency to improve outcomes of this rare urogenital malignancy.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Cancer Research Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | European Urology | ||||
Publisher: | Elsevier BV | ||||
ISSN: | 0302-2838 | ||||
Official Date: | November 2013 | ||||
Dates: |
|
||||
Volume: | Volume 64 | ||||
Number: | Number 5 | ||||
Page Range: | pp. 823-830 | ||||
DOI: | 10.1016/j.eururo.2013.03.044 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |